
Mitochondria-targeting peptide that binds to cardiolipin — stabilizes the inner membrane and restores ATP production in dysfunctional mitochondria.
Ranges cited in research literature. Not a usage recommendation. For research use only.
SS-31, known in the clinical literature as elamipretide (also MTP-131 or Bendavia), is an aromatic-cationic tetrapeptide with the sequence D-Arg–Dmt–Lys–Phe-NH2, where Dmt is 2',6'-dimethyltyrosine, a non-natural amino acid. It was designed by Hazel Szeto and Peter Schiller in the early 2000s — hence “SS” — and has an unusual property: it crosses membranes and concentrates in the inner mitochondrial membrane independently of membrane potential.
There it binds cardiolipin, the phospholipid unique to that membrane that organizes the respiratory-chain complexes. In damaged mitochondria cardiolipin becomes oxidized and cytochrome c loses its anchor; SS-31 stabilizes the interaction, improves electron-transport efficiency, reduces reactive-oxygen-species production and increases ATP synthesis. It is, in essence, a structural stabilizer of the mitochondrion rather than a classic antioxidant.
Stealth BioTherapeutics' clinical development spanned Barth syndrome, primary mitochondrial myopathy, heart failure, dry macular degeneration and Leber hereditary optic neuropathy, with mixed results: several Phase 3 trials missed their primary endpoints. In September 2025 the FDA granted elamipretide (Forzinity) accelerated approval for Barth syndrome, an ultra-rare cardiolipin disorder. That approval belongs to the branded medicine; Renova's SS-31 is a research reagent.
| Class | Mitochondria-targeting aromatic-cationic tetrapeptide (Szeto-Schiller peptide) |
| Sequence | D-Arg–Dmt–Lys–Phe-NH2 (Dmt = 2',6'-dimethyltyrosine) |
| CAS | 736992-21-5 |
| Names | Elamipretide · MTP-131 · Bendavia · Forzinity (brand) |
| Target | Cardiolipin in the inner mitochondrial membrane |
| Reported half-life | A few hours in plasma; prolonged mitochondrial accumulation |
| Regulatory status | FDA accelerated approval for Barth syndrome (Sept 2025) as a branded medicine; Renova product is RUO |
Yes. SS-31 is the research name (after Szeto and Schiller, its designers); elamipretide is the international nonproprietary name it received on entering clinical trials, and MTP-131 or Bendavia are development names. All designate the same tetrapeptide.
Its alternating structure of aromatic and cationic residues lets it cross the plasma membrane and accumulate in the inner mitochondrial membrane without depending on membrane potential, which is unusual. Once there it binds cardiolipin, a phospholipid found only in that membrane.
Mixed. In primary mitochondrial myopathy, heart failure and dry macular degeneration several Phase 2/3 trials missed their primary endpoints. In Barth syndrome the initial crossover trial was negative but the open-label extension showed sustained improvement, and in September 2025 the FDA granted accelerated approval for that ultra-rare indication.
Both act on the mitochondrion, but differently: MOTS-c is a signal encoded by the mitochondrion itself that activates AMPK; SS-31 is a synthetic peptide that physically stabilizes the inner membrane through cardiolipin. They are investigated separately.
Related reading: SS-31 (Elamipretide): The Mitochondria-Targeting Peptide · MOTS-c: The Mitochondrial Peptide Explained
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty